4 8 5 a r t i c l e s APOBEC3 (A3) proteins are single-stranded DNA cytosine deaminases that are part of a larger network of innate immune effector proteins that serve to limit the replication of many diverse parasitic elements including the AIDS virus . Up to seven family members, A3A, A3B, A3C, A3D, A3F, A3G and A3H, can be expressed in a single human cell 4 . A combination of overexpression, knockdown, knockout and separation-of-function studies have shown that A3D, A3F, A3G and A3H contribute to HIV-1 restriction and hypermutation in CD4 + T lymphocytes (refs. 5-7 and references therein). A3D, A3F and A3H catalyze C-to-U deamination in 5′-TC dinucleotide motifs, whereas A3G catalyzes deamination in 5′-CC motifs. These viral cDNA-deamination events lead to G-to-A mutations in hallmark GA and GG dinucleotide motifs, respectively. A3G has two structural domains: an N-terminal pseudocatalytic domain (NTD) and a C-terminal catalytic domain (CTD) 8, 9 . The CTD alone dictates the observed local dinucleotide preference 10-12 . The NTD is catalytically inert but still strongly binds RNA and single-stranded DNA and forms a ribonucleoprotein complex with the viral Gag protein, thus enabling encapsidation (examples in refs. 13-17).
a r t i c l e s Figure 1 Generation of soluble N-terminal Vif-binding domain of A3G. (a) Amino acid sequence similarities of APOBEC3 proteins. Amino acid sequences of APOBEC3 proteins were aligned by ClustalW 60 , and the branch length represents sequence similarity. A3 proteins are grouped as described previously 39 . A3C, A3F CTD and A3G NTD bind HIV-1 Vif, and all of them belong to the Z2 group. with Vif, and they belong to the same phylogenetic subgroup, the Z1 group 39 (Fig. 1a ). An alignment of A3A, A3B CTD and A3G CTD allowed us to generate a consensus Z1 amino acid sequence ( Supplementary Fig. 1a ). We expressed and purified the consensus Z1 protein from E. coli and found that it was soluble and folded. We used wild-type A3G NTD amino acid residues to replace consensus Z1 residues one at a time and then tested all of the resulting constructs for protein expression, solubility and stability. We used NMR to evaluate soluble derivatives for signal dispersion and homogeneity. Ultimately, we achieved 80% amino acid sequence identity to wild-type NTD without substantially compromising the solubility or quality of NMR spectra (Fig. 1b,c) . Additional wild-type A3G amino acids were not tolerated (Supplementary Fig. 1b,c) . We henceforth refer to this soluble A3G NTD construct as sNTD.
Solution structure of sNTD
We generated a series of 15 N, 13 C and/or 2 H isotope-labeled protein samples to determine the solution structure of sNTD with state-of-the-art NMR techniques combined with amino acid-specific labeling techniques 31, 40 (representative NMR spectra in Supplementary Fig. 2) . We subjected each sample to size-exclusion chromatography for purification and evaluated the monomeric status by the elution profile. sNTD eluted with a major peak corresponding to a molecular weight of 17 kDa and a minor peak corresponding to 47 kDa (Fig. 1b) ; the theoretical molecular weight of sNTD is 21 kDa. sNTD exhibited fair-quality NMR spectra with most amide proton signals resolved in a transverse relaxation-optimized spectroscopy (TROSY) 41 spectrum, although signal intensities were inhomogeneous, thus suggesting diverse dynamics throughout sNTD ( Supplementary  Fig. 3 ). Using conventional triple-resonance NMR spectra 40 , we assigned backbone signals ( 1 HN, 15 N, 1 Hα, 13 Cα and 13 C′) for 146 residues (81.1%) of sNTD. 24 residues were missing from TROSY spectra, owing to severe line broadening, thus suggesting conformational exchange. NOE signals and a 1 H/ 2 H-exchange experiment indicated that sNTD contains a β-sheet of five β-strands arranged in the order of β2(54-56)-β1(36-42)-β3(85-92)-β4(113-120)-β5(148-152), with β2-β1-β3 in an antiparallel orientation and β3-β4-β5 in a parallel orientation ( Supplementary Fig. 4 ). 1 H-1 H NOE patterns indicated that β2-β1 form an antiparallel β-sheet; however, only Y37 NH from β1 showed slow 2 H exchange with solvent, whereas F54 NH and G56 NH from β2 exchanged completely with solvent within 1 h ( Supplementary Fig. 4 and data not shown). Thus, hydrogen bonds between F54 NH and V39 CO, and between G56 NH and Y37 CO were weaker than that between Y37 NH and G56 CO, results indicating that the structure and motions of β2 are likely to be less restrained than in the other β strands.
We determined the sNTD solution structure with 1,609 distance and 106 dihedral-angle restraints (structural statistics summarized in Table 1 ). The structure of sNTD has six α-helices, including α1 (16) (17) (18) (19) , α2(68-75), α3(98-108), α4(131-140), α5(154-164) and α6(178-194), organized around the β-strands described above ( Fig. 2) . Secondary structures were well defined, although α1, β2 and α2 were less converged, as compared to other secondary structures ( Fig. 2a) . The poorer convergence for β2 was indicative of weaker hydrogen-bonding with β1. The loop between β1 and β2 (β1-β2 loop) was disordered because of insufficient NOE restraints. Residues located in the β1-β2 loop (E38, V39, K40, K42, G43, S45 and R46) and the α2-β3 loop (Q84, E85 and Y86) each showed two weak signals in TROSY spectra ( Supplementary  Fig. 3 ). Because the β1-β2 and α2-β3 loops face each other in the sNTD structure, these two loops may exchange between two conformations ( Fig. 2b) . npg a r t i c l e s
The overall structure of sNTD was similar to that of other A3 proteins, including A3A, A3C, A3F CTD and A3G CTD 12,31-38 ( Fig. 3a) . However, the sNTD structure also had several unique features. First, the start of α2 is residue 68 of sNTD, one residue after the conserved glutamate residue (E67), whereas in α2s of catalytically active A3 domains, the helix starts one residue prior to the conserved glutamate. This structural difference substantially affected the spatial positioning of E67, by causing the residue to be located too far from the Zn 2+ ion to participate in catalysis ( Fig. 3b) . Second, the α2 N terminus was tilted toward the C terminus of α3, an orientation not seen in any reported A3 catalytic-domain structures (Fig. 3c) . These two features provided a likely explanation for prior studies that assigned catalytic activity exclusively to the CTD 8, 9, 42 . Third, sNTD lacked a bulge structure present in the β2 region of A3A and A3G CTD (Fig. 3d) . The β2 strand of sNTD was shorter than in other A3s and was located in the position of β2′ of the β2-bulge-β2′ structure of A3A and A3G CTD ( Fig. 3d) .
We substituted 20% of wild-type residues to solubilize the NTD. Two-thirds of the substituted residues are located in loops, including ∆(M1-R11), Y13D, R14P, Y22N, L62D, ∆R78, A109Q, D111N, P112T, K113H, F126A, K141A, R142G, ∆(D143-R146), R169G, E170A, L171P, E173Q, N176D and N177G, whereas the remaining substitution are in helices, including F71L, H72S, W73L and F74V in α2; T101A in α3; C139A in α4; and P179D, K180E, Y181H, Y182S, I183Q, L184A, H186S, I187G and M188R in α6, with the exception of M149I in β2.
sNTD is catalytically inactive in vitro
Because our solubilization strategy started with the consensus sequence of several active deaminases, we next asked whether sNTD possessed catalytic activity, by using one-dimensional 1 H NMR spectra 11, 12 . For a positive control, we incubated the catalytically active A3G CTD variant (CTD 2K3A) 31 with substrate DNA (5′-ATTCCCAATT-3′) 12 and saw a signal corresponding to the uridine H5 proton emerge within 30 min at 5.72 p.p.m. ( Supplementary  Fig. 5 ). This result indicated that CTD 2K3A had catalyzed the first deamination reaction (5′-CCC to 5′-CCU). Within 24 h, CTD 2K3A completed the second deamination reaction, 5′-CCU to 5′-CUU, thus resulting in two H5 proton signals, one at 5.74 p.p.m. and the other at 5.81 p.p.m. (Supplementary Fig. 5e ). By contrast, sNTD did not cause changes to the NMR spectrum of the substrate DNA even after 24 h ( Supplementary Fig. 5f ). Thus, sNTD lacks detectable deaminase activity, consistently with prior studies demonstrating the catalytic inactivity of this domain 8, 9, 42 .
sNTD binds Vif
We used GST pulldown experiments to monitor the interaction between sNTD and VCBC coexpressed in E. coli. sNTD bound to the VCBC complex (Fig. 4a, lane 10) , and H43A and Y44A substitutions in Vif reduced binding to undetectable levels (Fig. 4a, lane 11 ). Because F126 of wild-type NTD had been substituted to an alanine in sNTD, in order to increase solubility, we reversed this mutation and tested binding to the VCBC complex. sNTD F126 bound more strongly than the original sNTD construct to the VCBC complex (Fig. 4a, lane 8 ), and this interaction became undetectable when we used Vif H43A Y44A instead of wild-type Vif (Fig. 4a, lane 9 ). The location of A126 appeared to be in the middle of the loop between β4 and α4, where it was exposed to solvent ( Fig. 4b) . This surface location was important because the A126F substitution was unlikely to alter either secondary-or tertiary-structural elements.
F126 is important for Vif-mediated degradation
We created a construct in which sNTD was fused to wild-type CTD (A3G sNTD-CTD) and tested whether this construct behaves similarly to wild-type full-length A3G in a Vif-mediated degradation assay ( Fig. 4c) . We used wild-type A3G as a positive control, which, as expected, demonstrated reduced protein levels in HEK293T cells when coexpressed with Vif (Fig. 4c, lane 3 ) than when expressed alone (Fig. 4c, lane 1) . The A3G protein level was restored by addition of protease inhibitor MG132 (Fig. 4c, lane 4) . We used a double mutation of H43A and Y44A in Vif ( Fig. 4c lane 5) and D128K in A3G (Fig. 4c, lane 9) as negative controls because these mutations have been shown to impair Vif-mediated degradation of A3G 18, 26, [43] [44] [45] [46] [47] . Interestingly, A3G sNTD-CTD protein levels were not reduced upon coexpression with Vif (Fig. 4c, lane 15 ). Because sNTD F126 bound to the VCBC complex more strongly than sNTD in vitro (Fig. 4a, lane 8) , we prepared a construct with sNTD F126 fused to wild-type CTD (sNTD F126-CTD) and tested its protein stability in a Vif-mediated degradation assay. sNTD F126-CTD exhibited reduced protein levels in the presence of Vif (Fig. 4c, lane 21) , which were restored by coexpression with Vif H43A Y44A (Fig. 4c, lane 23 ) or by treatment with MG132 (Fig. 4c, lane 22) . Furthermore, adding the Vif-antagonizing npg a r t i c l e s single-amino acid substitution D128K protected the sNTD F126 D128K-CTD construct from degradation by Vif (Fig. 4c, lane 27) .
Prior studies have suggested the importance of F126 in Vif binding and in Vif-mediated degradation of A3G 26, 28, 48 . Thus, these data indicate that a single-amino acid reversion (F126) can restore Vif susceptibility to the A3G sNTD-CTD construct and that the overall mechanism of Vif-mediated degradation is preserved in this construct.
sNTD lacks antiviral activity
We compared wild-type A3G, sNTD-CTD and sNTD F126-CTD constructs in HIV-1 restriction experiments (Fig. 4d) . As reported previously, wild-type A3G is packaged into vif-deficient HIV-1 particles, and it restricts viral infectivity in a dose-dependent manner (Fig. 4d, lanes 1-4) . Antiviral activity was strongly counteracted by Vif, as evidenced by less A3G in cells and viral particles, and mostly restored viral infectivity ( Fig. 4d, lanes 5-8) . In contrast, sNTD-CTD resisted Vif-mediated degradation and failed to package substantially into viral particles, despite near-wild-type A3G levels of cellular expression ( Fig. 4d , comparison of lanes 17-20 and 21-24). However, as described above in coexpression studies, the single-amino acid substitution A126F (sNTD F126-CTD), restored the susceptibility of this construct to Vif-mediated degradation but did not restore packaging and restriction activities ( Fig. 4d , comparison of lanes 9-12 and 13-16). These data confirmed that the sNTD F126-CTD construct is functional for Vif degradation but is compromised for packaging and restriction. Because packaging requires the formation of a ribonucleoprotein complex with Gag (examples in refs. [13] [14] [15] [16] [17] , and similar regions of A3G have been implicated in both Vif interaction and RNA binding, the sNTD F126 variant appeared to separate these two activities by preserving the capacity to be bound and degraded by Vif and by losing the capacity to bind RNA (which also manifests as packaging and restriction deficiencies).
Vif binding to sNTD differs in A3C and A3F
We used sNTD variants, E. coli coexpression and GST copurification as described above to identify amino acid residues required for interaction of sNTD with the VCBC complex. Substitutions Y19 at the C terminus of α1; I26, L27 and W34 in the α1-β1 loop; V58 and Y59 in the β2-α2 loop; and Y124, W127 and D128 in the β4-α4 loop decreased binding to the VCBC complex by >50% ( Fig. 5a and representative SDS-PAGE gel images in Supplementary Fig. 5g ). These residues substantially expanded the size of the A3G NTD surface area required for Vif interaction (Fig. 5b) . Interestingly, using a different experimental approach, Lavens et al. implicated a similar surface area (ref. 49 and Fig. 5c ). Thus, the A3G NTD Vif-binding surfaces appeared to be in distinct areas from those of the Vif-binding surfaces of A3C and A3F CTD, both of which are formed by residues located in the α2 and α3 helices 38 (Fig. 5d,e ).
DISCUSSION
We used sequence conservation and restorative mutagenesis to engineer a soluble variant of the A3G NTD, which is 80% identical to the wild-type enzyme (Fig. 1a) . This variant, like wild-type A3G NTD, is not catalytically active but still binds Vif and succumbs to Vifmediated degradation ( Fig. 4 and Supplementary Fig. 5f ). This engineering approach, although labor intensive, is applicable to other systems that have evaded structural characterization because of protein solubility issues. We used NMR spectroscopy to solve the structure of sNTD, generating what is, to our knowledge, the first structure of an APOBEC3 noncatalytic domain and the first structure of the Vif-binding domain of A3G. Our results suggest a mechanistic basis for the lack of 37 , A3C (PDB 3VOW) 38 , A3F CTD (PDB 4IOU) 35 and A3G CTD (PDB 3IR2) 34 , with zinc displayed in purple. (b) Enlarged view of the APOBEC3 zinc-binding sites from a. The side chains of zinc-coordinating residues are rendered with ball-and-stick representation. For each structure, the top faces the protein interior, and the bottom is accessible to solvent. Zinc is shown as gray spheres. (c) Comparison of the α2 and α3 helices. α2 and α3 of sNTD (green) are superimposed with those of other APOBEC3 proteins: A3A (PDB 2M65) 37 , A3C (PDB 3VOW) 38 , A3F CTD (PDB 4IOU) 35 and A3G CTD (PDB 3IR2) 34 . Zinc is displayed in green (sNTD) or gray (other A3s). (d) Comparison of the β1-bulge-β2 regions of sNTD and other APOBEC3 proteins. Each image shows sNTD (green) superimposed on another A3-domain protein (gray). npg a r t i c l e s catalytic activity. Zn 2+ is coordinated by residues H65, C97 and C100 at the protein interior (Fig. 3b) , and it contacts the hydrophobic side chains of L35, W90, I92 and M104 (Supplementary Fig. 6a) . These interactions reduce accessibility for a putative target cytosine because the pocket volume of the Zn 2+coordinating region is reduced in comparison to that of the A3G CTD ( Supplementary  Fig. 6b) . The active site pocket volume of the A3G CTD is ~400 Å 3 , whereas that of sNTD is ~100 Å 3 , which is smaller than the volume of a cytosine nucleobase. This result supports the general trend observed for catalytically active and inactive domains 50 . In addition, conserved E67 of sNTD is not in a position in which Zn 2+ coordination is possible, thus preventing E67 from having a catalytic role (ref. 51, Fig. 3b and Supplementary Fig. 6a ). This altered position can be attributed to changes at the N terminus of the α2 helix, where A3G NTD has a proline at residue 66 just before E67 that shortens this helix so that it begins at M68. In all catalytically active A3 domains, the helix begins at A66.
To make a soluble NTD, we had to introduce four amino acid substitutions in α2 (F71L, H72S, W73L and F74V), although these are conserved mutations among APOBEC3 proteins (Supplementary Fig. 6c ). Residues 71 and 74 interact with F70 (α2), W90 (β3) and F107 (α3), and F70, W90 and F107 interact with Y37 (β1), V39 (β1) and V88 (β3). Together, these residues form a hydrophobic core that stabilizes the β1-α2-β3-α3 structure (Supplementary Fig. 6d ). All known A3 protein structures have similar hydrophobic cores involving corresponding residues 12, [31] [32] [33] [34] [35] [36] [37] [38] . Residues 72 and 73 are not involved in the hydrophobic cores of known A3 structures, and we have shown that these residues can be substituted with alanine without compromising the catalytic activity of the A3G CTD 52 . Thus, substitutions at residues 71-74 are unlikely to be responsible for the unique structural features of α2 and α3 of sNTD.
The known Vif H43A Y44A 26 variant disrupts wild-type A3G binding and also does not permit binding to sNTD, thus suggesting that contacts made through H43 and Y44 are maintained between sNTD 6 and 7) , GST-fused sNTD F126 (lanes 8 and 9) or GST-fused sNTD (lanes 10 and 11) expressed together with untagged CBF-β, elongin BC and wild-type HIV-1 Vif or Vif H43A Y44A. Lanes 1-5 show reference bands for the expressed protein.
(b) Locations of D128 and A126 (highlighted in green) in the sNTD structure. (c) Vif-mediated degradation assay with wild-type A3G (A3G) (lanes 1-6); A3G with D128K substitution (A3G D128K) (lanes 7-12); sNTD fused with wild-type CTD (sNTD-CTD) (lanes 13-18); sNTD with A126F substitution, fused with wild-type CTD (sNTD F126-CTD) (lanes [19] [20] [21] [22] [23] [24] ; and sNTD with A126F and D128K double substitutions, fused with wild-type CTD (sNTD F126 D128K-CTD) (lanes [25] [26] [27] [28] [29] [30] . α-tubulin is a loading control. Vif (WT) is wildtype Vif, and Vif H43A Y44A contains alanine substitutions of H43 and Y44. Treatment with MG132 is indicated. (d) Single-cycle infectivity experiment comparing wild-type A3G and full-length variants with sNTD F126-CTD and sNTD-CTD. The histogram reports the infectivity of Vif-deficient (Vifxx) or Vifproficient (WT) HIV-1 IIIB produced in HEK293T cells expressing the indicated A3G-myc construct (0, 25, 50 and 100 ng). Graph shows mean ± s.d. (n = 3 independent cell cultures). The corresponding immunoblots show expression levels of relevant proteins in cell lysates (anti-myc for A3G-myc; anti-Vif; and anti-α-tubulin) and virus-like particles (VLPs; anti-myc for A3G-myc; and anti-p24). α-tubulin and p24 are loading controls. Uncropped images are shown in Supplementary Data Set 1. npg a r t i c l e s and Vif. However, sNTD fused to wild-type CTD was largely resistant to Vif-mediated degradation. We found that A126 was responsible for this reduction because replacement of this alanine with endogenous phenylalanine increased interaction with the VCBC complex and restored susceptibility to Vif-mediated degradation. These results confirmed the importance of A3G F126 in Vif binding and, together with additional mutant data, demonstrated that the sNTD construct is a good structural mimic of wild-type A3G NTD.
A caveat of sNTD function is that neither sNTD-CTD nor sNTD F126-CTD was able to incorporate into viral particles or restrict HIV-1 infection. Encapsidation requires interaction with RNA and Gag protein (examples in refs. 13, 14, [53] [54] [55] . The failure of sNTD variants to encapsidate is most probably due to an abrogated interaction with RNA because we could not detect interaction between sNTD and RNA in a phosphate buffer containing 100 mM NaCl (data not shown). This loss may be due to deletion and/or substitution of basic residues, including K2, R6, R11, R14, R78, K113, K141, R142, R146, R169 and K180 in sNTD (Supplementary Fig. 1 ). Future studies may be able to use sNTD as a starting point to determine residues essential for encapsidation and RNA binding.
The Vif-binding regions of sNTD identified by this study, including α1-β1, β2-α2 and β4-α4 loops, provide a structural binding site for Vif and validate previous studies 26, 49, 56, 57 with wild-type A3G (Fig. 5b,c) . The β4-α4 loop contains residues 124-YYFWD-128, which are known to be important for Vif-mediated A3G degradation 26, 58 . Structures of the A3C and A3F Vif-binding domains have been solved, and their Vif-binding surfaces have been mapped by mutagenesis, coimmunoprecipitation and degradation assays to a different surface 35, 36, 38, 59 . In these cases, Vif was proposed to bind a continuous surface located on the α2 and α3 helices of A3F CTD and A3C, away from the catalytic zinc (Fig. 5d,e ). A3G residues F74, L80, Y86 and F107 are conserved in A3C, and they were previously found to be critical for A3C binding to Vif but, consistently with our results, not to be important for Vif-mediated degradation of A3G 38 . Previous studies have shown that a negatively charged region around D128 appears to be important for binding to Vif (Supplementary Fig. 6b ) because substitution of this amino acid abrogates binding to Vif [26] [27] [28] [29] . The A3G CTD has a more positively charged profile in the corresponding area that probably interferes with binding to Vif 30 (Supplementary Fig. 6b) . In summary, we report the structure of the Vif-binding domain of A3G (sNTD), which further elaborates a new mode of Vif binding and provides a substrate for future structural studies of the entire A3G-Vif ligase complex as well as for drug discovery.
METHODS
Methods and any associated references are available in the online version of the paper. Supplementary Figure 5g (experiments were repeated three times with independent cell cultures). (b) sNTD structure with red highlighting indicating residues whose substitution reduced sNTD binding to the VCBC complex by >50%. F126 is highlighted in green. (c) Structure with red highlighting indicating residues whose substitution resulted in >50% reduction of A3G Vif binding, as previously reported 49 (c). (d,e) Structure with red highlighting indicating residues of A3C CTD (d) and A3F CTD (e) whose substitution resulted in >50% reduction in Vif binding 38 .
npg a r t i c l e s surface-charge distribution and binding-pocket volumes of the NTD structure. J.Z. provided support in harvest assays. L.C. and M.H. provided support with preparation of expression plasmids and with the Vif binding assay in E. coli. T.K., E.M.L., S.M.D.S., C.A.S., R.S.H. and H.M. contributed to writing and editing the manuscript.
